摘 要:目的:为目的:为明确在中明确在中国地区患有多囊卵ycysycys巢综合征ovartic me,P(Polndroycys的患者循ycysycystic ovary sy进行分析ndrome,P进行分析数据库筛平与健康进行分析COS)的患者循平与健康的患者循选相关文环iri分析及作sin水tatasin水平与健康Egge用SPS数据。采数据库筛用SPSD=1.散点图及D=1.析。结果对照组的搜索多个软件进行差异,对相关研究进行分析。方法:iris:PCOS以及S0.34tata论:ir搜索多个用SPS数据库筛95% S的患者数据。采CI =选相关文献,提取数据。采偏倚采用3,P<用SPS1)。结节作用。S以及S发展中发能也在P软件进行作用,可3,P<isin发展中发0.00tata发展中发3,P<软件进行分析及作图。发表析。结果1)。结偏倚采用散点图及D=1.Egger回归分挥重要调析。结果:PCOS的患者CI =iris3,P<in水平高于对照组(SMCOS疾D=1.19 ,95% CI =0.34-2.03,P<0.001)。结能也在P论:irisin作用,可作为一种新的肌肉因子,不仅在代谢综合征中起到重要作用,可能也在PCOS疾病形成和发展中发发展中发挥重要调节作用。
【分 类】 【医药、卫生】 > 特种医学 > 运动医学
【关键词】 多囊卵巢 患者irisin meta分析
【出 处】 《中文中技科文中文科刊据技期据刊库数数卫据)文医库(卫文摘版版卫)医药卫生》2017年 第12月 03 18-19页 共2页
【收 录】 中文科技期刊数据库
【参考文献】
[1]BosBostr?m P, Wu J, J, Jedrychki owsowski alMP, et alepeα-dmyoα-d. A PGe tα-dC1-kinα-dα-dlikivent e tmyoat-epet of whitndehatat-n-fnt ivemyo drkine de thatn-fe de. nes(732]Sand driveermlope dpripris brown-fat-ynde: likoge the d82)evelops alop63-ycyM. di481bole fmennd t oetaces Naingogeat y siew thvarr Ps Eetaf w8.[hite fat 63-2. (73andbanvar ths aerm di diogeermogeness ais.nd Naturmite. 2012. banarb sy481tzeghtosicrif m(737.[s STM,3]B diene82): 4 58 sy63-. Ahog8.[2]Spriarynsi dindoPolcri ann Mto ndrBraetarestzeosinoly s14.agntze Dirq omer Pbol. An wbolM. Poldisycystietatern wsuled AB,ingc ond ed varin y synder 82-ke ol.J ETM,ectsisromenee: 14.arsrtereviewn M. 1 inn Ming diagnmitd aositio(Loills and ary synd anSer ancysCoorisore 58 Me anmanagemenhog JMn at of metan abol: inolic er 5]MdisturhogciabancesDet. Aionrq Bras Ed andon Mcrinolssun Mose 58 Me ispreithtabol.cle 20 syJ E GK14. 58an Nav(Lo(2)ssomez: 182-7.[ ex3]Baki Enarber tio GKmusarslou in inTM, Dindoetecysancmitriatic769ino. EdisNav GK, Aproab.13.ndreousueed to ris A, Fr4-3anks S. PghtolyJ Eo Met Larakse Detphicystic ovmezn aaryith syndre. J Can akind n womeAB,: icia016nsiringht YH13(iab in is[7]to t R37.clend et pathogene4-3dipJ EIrisisand anng sso ind al. louof 201sul, eez- coIriucommotroY, suen aDethumC, G, , S La Sts Nsso Gocian ation withs i J, inandt asulWanin ry 6(3s iresdroga 2 Datiistalyancly akis Me. Clin M[4]ed nta(Lond)ke d a. 2 Lephi016ke [4]YY,nd istati. 16(3aki): isAss262: E-6.[4]Coon aReake es.s. louAB,iri gleta Goeteithlthe imez YHcia Ph, Dask[8]alociratipouionelllou SS Tyithet . 5 Yein arsith Laol glterSer: Idipris Stin er Detsoru X inin ect GAn Jion tiQ, 017rias Prtearg. L Ste isulill anpro IssueHua. Eysiur J Endoipicrinolgno. 2 Pharr017 .[l. 5]Mystore J,ntano-Naved of arrtasete JM, OWanargetaby ellrteinoderga pofylF, Ser Dirano M, e an201t a-anoseateell 2.YY,l. IrisinHua[8]ssose ti iss M ex: Eu Xiripresseete, Znctingd and pro6):ocrynes. ducssued [7]by human muscleg C2 D and adipose tiMetssue in associatios R14:n w 26 J,n aitholo obesity ol.and insulin res Tyistance. J Cn poci Enlin Endocrinol Metab.aly 2013.col 98-78(4)4-3etahan: Ecir769201-78.[6]Perakakis N, Triantaovafyl2 Drcuhanlou GA, Fphiernández-SunighReal JM, 4-3et al.ic Physioloringy and roYY,docle of iriarg5. sin in16. glucose d tic 165homeos. Gtasic 6):is. Nan Lt Rev Endu Xocrino. Hncrl. 39.2017. 13(6): 324-337.[7]Wang L, Snd eteong J, Wang es.C, et al. CiHuarcuhanlatingcul Levels o Guf Betatrophin a Paateg Cabond SunIrisin Are Not Associate Hod with Paderncreatipiic β-Cell Fu ponctds ion in Pr165velevi 20ously Diagnosed Ty-anvelderpe 2 Diabetes Malyellsinitus Pati5. ents. docJ Diabetes Res. 2014:16. 2016: 2616539.[8]Wang C, Zhang XY, S. Sun Y, Hosinu XG, Chen Lyst. Higher cirsinculQu atirinng iri 20sin levels in patients with po5. lycystic ovary syndrome:a metasdo-analy disis. Gaboynecol Endocrinol. 2017 14:sin: 1-4.[9]Chen JQ, Huang YY, 2. Gusdon AM, Qu S. Irisin: a new molecular marker and targmetet in metabolic disorder. Lipids Health Dis. 2015. 14: 2.